Biologics in SAPHO syndrome: A systematic review

• Published in: Seminars in arthritis and rheumatism Vol. 48; no. 4; pp. 618 - 625
• Main Authors: Daoussis, Dimitrios, Konstantopoulou, Georgia, Kraniotis, Pantelis, Sakkas, Lazaros, Liossis, Stamatis-Nick
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2019
• Subjects: Abatacept; Adalimumab; Anakinra; Anti-TNF; Biologics; Canakinumab; Certolizumab; Etanercept; Golimumab; IL-1; IL-17; IL-23; IL-6; Infliximab; Rituximab; SAPHO; Secukinumab; tocilizumab; Treatment; Ustekinumab; Golimumab; IL-1; Certolizumab; Anti-TNF; Ustekinumab; Rituximab; Secukinumab; Canakinumab; IL-23; IL-6; tocilizumab; Treatment; Infliximab; Etanercept; Abatacept; Biologics; IL-17; SAPHO; Adalimumab; Anakinra

The SAPHO syndrome is a relatively rare clinical entity characterized by a wide range of dermatological and musculoskeletal manifestations. Biologics have been used in cases refractory to conventional treatment. We present herein a patient with refractory to treatment SAPHO syndrome who exhibited a...